Psychiatric diagnosis

Alzheimer's Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer's

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Dementia, Aging-associated diseases, Alzheimer's disease, Alzheimer's Drug Discovery Foundation, Biomarker, Ronald Lauder

The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.

Key Points: 
  • The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
  • Recent research shows that Alzheimer'salso causes subtle early changes in aspects of behaviour such as sleep, speech, interactions, and movement.
  • While undetectable to the human eye, these changes can now be picked up by commercially available digital technologies.
  • Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Improving Air Quality Reduces Dementia Risk, Multiple Studies Suggest

Retrieved on: 
Monday, July 26, 2021
Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Branches of biology, Aging-associated diseases, Abnormal psychology, Pollution, Dementia, Air pollution

While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.

Key Points: 
  • While research has linked air quality and cognition previously, these new data at AAIC 2021 explore how air pollutants might impact dementia and what reducing them might mean for long-term brain health.
  • "But what's exciting is we're now seeing data showing that improving air quality may actually reduce the risk of dementia.
  • Air Quality Improvement May Slow Cognitive Decline and Reduce Dementia Risk in Older U.S. Women
    Although studies have found that improved air quality is associated with better respiratory health and longer life expectancy, it's unknown if improved air quality can also improve brain health.
  • Association of air quality reduction with incident dementia: effects of natural course and hypothetical air pollutant interventions using g-computation.

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

Retrieved on: 
Monday, July 26, 2021
Geriatrics, Parkinson's disease, Psychiatric diagnosis, Branches of biology, Medicine, Clinical medicine

ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.

Key Points: 
  • Following the review, the Agency met with the Company on July 22, 2021, and granted the company permission to begin evaluation of IkT-148009 in Parkinson's patients.
  • "The extension of our Phase 1 study of IkT-148009 for the treatment of Parkinson's disease into patients is an important milestone for Inhibikase.
  • Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.
  • Inhibikase is currently evaluating the safety, tolerability and pharmacokinetics of IkT-148009in older and healthy subjects and Parkinson's patients.

SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome

Retrieved on: 
Monday, July 26, 2021
Health sciences, Health, Clinical research, Design of experiments, Medical research, Psychiatric diagnosis, Tourette syndrome, Clinical trial, Placebo-controlled study

TEL AVIV, Israel, July 26, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110.

Key Points: 
  • TEL AVIV, Israel, July 26, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110.
  • The company is currently in contact with two clinical sites that will potentially host and conduct the clinical study.
  • Tourette Syndrome (TS) is a movement and neurobehavioral disorder characterized by motor and vocal chronic tics with onset before age 18.
  • SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI-110 in a randomized, double-blind, placebo controlled, cross-over study.

FTC Votes to Reverse Course on Repeal of Fabric Care Labels

Retrieved on: 
Saturday, July 24, 2021
Articles, Criminology, Labeling theory, Psychiatric diagnosis, Social constructionism, Symbolic interactionism, Repeal, Academic disciplines

Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.

Key Points: 
  • Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.
  • After careful consideration, I believe the record supports retaining the Care Labeling Rule and that it should not be rescinded.
  • Many individuals and small businesses opposed the repeal, emphasizing that buyers rely on labels to help extend the life of their clothes.
  • The Commission voted 5-0 to issue a statement to notify the public that it will not repeal the Care Labeling Rule, as previously proposed.

FTC Votes to Reverse Course on Repeal of Fabric Care Labels

Retrieved on: 
Saturday, July 24, 2021
Articles, Criminology, Labeling theory, Psychiatric diagnosis, Social constructionism, Symbolic interactionism, Repeal, Academic disciplines

Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.

Key Points: 
  • Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.
  • After careful consideration, I believe the record supports retaining the Care Labeling Rule and that it should not be rescinded.
  • Many individuals and small businesses opposed the repeal, emphasizing that buyers rely on labels to help extend the life of their clothes.
  • The Commission voted 5-0 to issue a statement to notify the public that it will not repeal the Care Labeling Rule, as previously proposed.

FTC Votes to Reverse Course on Repeal of Fabric Care Labels

Retrieved on: 
Saturday, July 24, 2021
Articles, Criminology, Labeling theory, Psychiatric diagnosis, Social constructionism, Symbolic interactionism, Repeal, Academic disciplines

Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.

Key Points: 
  • Following that action, the FTC received more than 200 comments, with an overwhelming majority opposed to the repeal of the rule.
  • After careful consideration, I believe the record supports retaining the Care Labeling Rule and that it should not be rescinded.
  • Many individuals and small businesses opposed the repeal, emphasizing that buyers rely on labels to help extend the life of their clothes.
  • The Commission voted 5-0 to issue a statement to notify the public that it will not repeal the Care Labeling Rule, as previously proposed.

Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Friday, July 23, 2021
Branches of biology, Biology, Medicine, Monoclonal antibodies, Treatment of Alzheimer's disease, Alzheimer's disease, Cognitive disorders, Psychiatric diagnosis, Aducanumab, Biomarker, Disease

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • The companys contributions to the congress include four presentations on ADUHELM data and a total of 11 abstracts.
  • The company will also lead a late-breaking presentation on the design of the real-world observational Phase 4 study in Alzheimers disease, a prospective registry of ADUHELM, called International Collaboration for Real-World Evidence in Alzheimers Disease (ICARE AD-US).
  • Poster presentation: Reduction in Biomarkers of Alzheimers Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline virtual poster #57499.

Parkinson's Disease in the US: Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Parkinson's disease, Psychiatric diagnosis, Branches of biology, Aging-associated diseases, Health, Geriatrics, Disease

The "Parkinson's Disease - US Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease - US Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Parkinson's disease market Size from 2018 to 2030 in the United States market.
  • The report also covers the current Parkinson's disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
  • The disease epidemiology covered in the report provides historical and forecasted Parkinson's disease epidemiology segmented as the Total Prevalent Cases of Parkinson's disease, Gender-specific Cases of Parkinson's disease, Severity-specific Prevalence of Parkinson's disease, Age-specific Cases of Parkinson's disease, and Prevalent Cases of Parkinson's Disease based on the onset.

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)

Retrieved on: 
Thursday, July 22, 2021
Psychiatry, Branches of biology, Psychiatric diagnosis, Health sciences, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Alzheimer's disease, Clinical trial

This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.

Key Points: 
  • This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimers disease and other dementias.
  • Cyclerion identified changes in electrophysiological measures in the recent Phase 1 Translational Pharmacology study and will be evaluating electrophysiological and cognitive endpoints in the Phase 2a study in participants with Alzheimers disease with vascular pathology.
  • Title: Clinical trial design for a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimers disease with vascular pathology
    The poster presentation will be available beginning at 8 a.m. MT / 10 a.m.
  • The poster will also be available on the News & Events page of the Cyclerion website https://ir.cyclerion.com/news-events/event-calendar .